Efficacy of Adalimumab Across Subgroups of Patients with Moderate-to-severe Chronic Plaque Psoriasis of the Hands And/or Feet: Post Hoc Analysis of REACH

Overview

Journal J Eur Acad Dermatol Venereol

Specialty Infectious Diseases

Date 2013 Jun 25

PMID 23790018

Citations 14

Authors

Y Poulin

J J Crowley

R G Langley

K Unnebrink

O M Goldblum

W C Valdecantos

Affiliations

Soon will be listed here.

Abstract

Background: The Randomized Controlled Evaluation of Adalimumab in Treatment of Chronic Plaque Psoriasis of the Hands and Feet (REACH) trial demonstrated that adalimumab was efficacious and well-tolerated for the treatment of hand and/or foot psoriasis through 28 weeks.

Objective: To evaluate the effects of patient baseline characteristics on efficacy of adalimumab treatment of hand and/or foot psoriasis.

Methods: Patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet were randomized 2 : 1 to adalimumab or placebo during the 16 week, double-blind period of REACH. Primary endpoint was percentage of patients achieving Physician's Global Assessment of the hands and/or feet of clear/almost clear at week 16. Post hoc analyses evaluated effects of baseline patient characteristics on the primary endpoint. Patients with nail psoriasis at baseline were assessed for association of Nail Psoriasis Severity Index (NAPSI) 50 response with efficacy outcomes at week 16.

Results: Seventy-two patients (49 adalimumab : 23 placebo) were analysed. Greater percentages of adalimumab-treated patients achieved the primary endpoint vs. placebo across all subgroups. Among 31 patients with nail psoriasis, a greater percentage of adalimumab-treated patients achieved NAPSI 50 (56.5%) vs. placebo (12.5%) at week 16. In adalimumab-treated patients, greater percentages of NAPSI 50 Responders vs. Non-responders achieved the primary endpoint, and had greater improvements in erythema, scaling, induration and fissuring, Dermatology Life Quality Index, and pain scores.

Conclusions: Adalimumab was efficacious in treating chronic plaque psoriasis of the hands and/or feet over 16 weeks, regardless of baseline characteristics. Marked improvement in nail psoriasis among adalimumab-treated patients correlated with significant improvements in skin disease and patient-reported outcomes.

Citing Articles

Nail Psoriasis: Clinical Features and Severity Assessment.

Youn S Ann Dermatol. 2024; 36(4):191-196.

PMID: 39082654 PMC: 11291102. DOI: 10.5021/ad.24.026.

Biologics and Biosimilars in Psoriasis.

Ahmed S, De A, Das S, Manchanda Y Indian J Dermatol. 2023; 68(3):282-295.

PMID: 37529455 PMC: 10389141. DOI: 10.4103/ijd.ijd_421_23.

Efficacy and Safety of Nail Psoriasis Targeted Therapies: A Systematic Review.

Hwang J, Ricardo J, Lipner S Am J Clin Dermatol. 2023; 24(5):695-720.

PMID: 37209391 DOI: 10.1007/s40257-023-00786-4.

Therapy of PsO in Special Subsets of Patients.

Di Cesare A, Ricceri F, Rosi E, Fastame M, Prignano F Biomedicines. 2022; 10(11).

PMID: 36359399 PMC: 9687729. DOI: 10.3390/biomedicines10112879.

Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments.

Blome C, Augustin M, Klein T Am J Clin Dermatol. 2021; 22(6):747-755.

PMID: 34383273 PMC: 8566428. DOI: 10.1007/s40257-021-00622-7.

References

Brunasso A, Salvini C, Massone C . Efalizumab for severe palmo-plantar psoriasis: an open-label pilot trial in five patients. J Eur Acad Dermatol Venereol. 2009; 23(4):415-9. DOI: 10.1111/j.1468-3083.2008.03062.x. View

Clark L, Lebwohl M . The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2007; 58(3):443-6. DOI: 10.1016/j.jaad.2007.11.011. View

Leonardi C, Langley R, Papp K, Tyring S, Wasel N, Vender R . Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2010; 147(4):429-36. DOI: 10.1001/archdermatol.2010.384. View

Handa S . Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails. Indian J Dermatol Venereol Leprol. 2010; 76(6):634-44. DOI: 10.4103/0378-6323.72455. View

Cohen D, Scherschun L . Case reports: practical experience with efalizumab in hand and foot psoriasis. J Drugs Dermatol. 2008; 6(12):1224-30. View

Langley R, Saurat J, Reich K . Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. J Eur Acad Dermatol Venereol. 2011; 26(3):373-81. DOI: 10.1111/j.1468-3083.2011.04349.x. View

Ashcroft D, Wan Po A, Williams H, Griffiths C . Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999; 141(2):185-91. DOI: 10.1046/j.1365-2133.1999.02963.x. View

Adisen E, Tekin O, Gulekon A, Gurer M . A retrospective analysis of treatment responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol. 2009; 23(7):814-9. DOI: 10.1111/j.1468-3083.2009.03197.x. View

Weinberg J . Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Cutis. 2003; 72(5):396-8. View

10.

Lior S, Grigory K, Pnina S, Joseph S, Felix P . Therapeutic hotline. Alefacept in the treatment of hyperkeratotic palmoplantar psoriasis. Dermatol Ther. 2010; 23(5):556-60. DOI: 10.1111/j.1529-8019.2010.01361.x. View

11.

Pettey A, Balkrishnan R, Rapp S, Fleischer A, Feldman S . Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003; 49(2):271-5. DOI: 10.1067/s0190-9622(03)01479-8. View

12.

Greaves M, Weinstein G . Treatment of psoriasis. N Engl J Med. 1995; 332(9):581-8. DOI: 10.1056/NEJM199503023320907. View

13.

Di Lernia V, Guareschi E . Successful treatment of hand and foot psoriasis with infliximab. Dermatol Online J. 2010; 16(7):8. View

14.

Rigopoulos D, Gregoriou S, Lazaridou E, Belyayeva E, Apalla Z, Makris M . Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol. 2009; 24(5):530-4. DOI: 10.1111/j.1468-3083.2009.03453.x. View

15.

Au S, Goldminz A, Kim N, Dumont N, Michelon M, Volf E . Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatolog Treat. 2012; 24(3):179-87. DOI: 10.3109/09546634.2012.672710. View

16.

Menter A, Gordon K, Leonardi C, Gu Y, Goldblum O . Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010; 63(3):448-56. DOI: 10.1016/j.jaad.2009.09.040. View

17.

Menter A, Tyring S, Gordon K, Kimball A, Leonardi C, Langley R . Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2007; 58(1):106-15. DOI: 10.1016/j.jaad.2007.09.010. View

18.

Farley E, Masrour S, McKey J, Menter A . Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009; 60(6):1024-31. DOI: 10.1016/j.jaad.2008.11.910. View

19.

Patsatsi A, Kyriakou A, Sotiriadis D . Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. J Dermatolog Treat. 2011; 24(2):96-100. DOI: 10.3109/09546634.2011.607796. View

20.

Fabroni C, Gori A, Troiano M, Prignano F, Lotti T . Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients. J Eur Acad Dermatol Venereol. 2010; 25(5):549-53. DOI: 10.1111/j.1468-3083.2010.03826.x. View